Verrica Pharmaceuticals

2024 saw FDA approvals for treatments including berdazimer gel for molluscum contagiosum, dupilumab for atopic dermatitis, lifileucel for melanoma, Juvéderm Voluma XC for temple hollows, spesolimab-sbzo for psoriasis, tralokinumab-ldrm for AD, and sofpironium for hyperhidrosis, marking advancements in medical therapies.

Verrica Pharmaceuticals reports Q4 2024 YCANTH dispensed applicator units exceeded previous quarter despite cost reductions. The company notes significant distributor inventory reduction and plans to launch a single applicator configuration in Q1 2025 to enhance accessibility and reduce costs. Verrica expands distribution through local pharmacies and aims to increase patient access via buying groups, hospitals, and government entities. The company continues to advance its pipeline, including YCANTH for common warts and VP-315 for basal cell carcinoma.

Lytix Biopharma AS plans a private placement raising NOK 90-100M and a retail offering via PrimaryBid up to EUR 1M at NOK 6.00 per share. Proceeds will fund studies, manufacturing, and corporate purposes, extending cash runway through 2025. Pre-commitments total NOK 75M, with additional guarantees ensuring minimum NOK 100M. The private placement targets selected investors, while the PrimaryBid offering is for public in Norway, Denmark, and Finland. Applications open 16-17 December 2024. Allocation and settlement details are provided, with lock-up arrangements and potential subsequent offerings considered.

Verrica Pharmaceuticals faces challenges with YCANTH's launch, management changes, and strategic uncertainties. YCANTH's commercial rollout hurdles include payer coverage barriers and competition. The company is addressing issues through expanded distribution and supportive measures like the J-Code. Management changes and a strategic review aim to salvage YCANTH's market position, manage costs, and restore the balance sheet. VP-315 shows promise for basal cell carcinoma, potentially diversifying the portfolio. Financial performance is critical for 2024, with market dynamics presenting both challenges and opportunities.

Torii Pharmaceutical submits NDA for TO-208 (VP-102/YCANTH) in Japan, targeting molluscum contagiosum. Phase III trial showed efficacy and safety, with a strategic partnership between Torii and Verrica Pharmaceuticals driving the application. YCANTH is already FDA-approved and available in the US.

Verrica Pharmaceuticals Inc. announced Torii Pharmaceutical Co. Ltd. submitted a New Drug Application in Japan for TO-208, a cantharidin-based treatment for Molluscum Contagiosum, potentially becoming the first approved treatment in Japan. TO-208, known as YCANTH® in the U.S., addresses a significant unmet medical need for an estimated 1.6 million affected people in Japan, primarily children.

Verrica Pharmaceuticals announces Torii Pharmaceutical's NDA submission for TO-208 to treat Molluscum Contagiosum in Japan, addressing 1.6 million cases.

Lytix Biopharma presented updated results from its basal cell carcinoma study at the DNB Nordic Healthcare conference, showing a 97% overall response rate for LTX-315. The study also reported an 86% tumor size reduction and 51% complete clearance rate. The company aims to advance to phase III, targeting a $11.5 bn global market by 2028.

Lytix Biopharma reports Q3 2024 progress, including positive clinical results in basal cell carcinoma and melanoma, and strategic advancements towards commercialization. LTX-315 shows 86% tumor size reduction in BCC and 40% disease control in melanoma. A new phase II study for early-stage melanoma and an improved LTX-401 formulation are underway. Cash reserves expected to last into 2025.